Diminished responsiveness of homosexual men to antiviral therapy for HBsAg-positive chronic liver disease.
To identify factors predicting response to antiviral therapy, we reviewed the clinical features of 38 male hepatitis B surface antigen (HBsAg) carriers who received adenine arabinoside or lymphoblastoid interferon. All patients were followed for one year or longer. Response was defined as loss of hepatitis B e antigen, hepatitis B virus DNA and DNA polymerase from the serum. Only 2 of 19 (11%) homosexual men responded, compared with 10 of 19 (53%) heterosexual men (P less than 0.02). Both responders in the homosexual group had received lymphoblastoid interferon. None of the 13 homosexual men, but 8 of 16 heterosexual men, responded to adenine arabinoside or its monophosphate (P less than 0.01). Responders to antiviral therapy had higher (P less than 0.05) serum levels of aspartate aminotransferase (median 115, range 51-344) than did non-responders (median 83, range 32-181). The decreased responsiveness of homosexual men to antiviral therapy may be a result of more severe immunologic abnormalities in homosexual than in heterosexual men with HBsAg-positive chronic liver disease.
D M
DM
Novick
A S
AS
Lok
H C
HC
Thomas
D000328:Adult; D001219:Aspartate Aminotransferases / Q000097:blood; D002353:Carrier State / Q000201:enzymology / Q000276:immunology / Q000628:therapy*; D002908:Chronic Disease; D006509:Hepatitis B / Q000201:enzymology / Q000276:immunology / Q000628:therapy*; D006514:Hepatitis B Surface Antigens; D006716:Homosexuality; D006801:Humans; D007111:Immunity, Cellular; D007370:Interferon Type I / Q000627:therapeutic use; D008107:Liver Diseases / Q000201:enzymology / Q000276:immunology / Q000628:therapy*; D008297:Male; D014740:Vidarabine / Q000627:therapeutic use; D001084:Vidarabine Phosphate / Q000627:therapeutic use
D006514:Hepatitis B Surface Antigens; D007370:Interferon Type I; D001084:Vidarabine Phosphate; D001219:Aspartate Aminotransferases; D014740:Vidarabine